ENSPRYNG is a prescription medication approved for NMOSD in AQP4-IgG(+) adults that has been proven to reduce the risk of relapse. It is also the only self-administered subcutaneous injection given under the skin for NMOSD. If your healthcare provider determines it is appropriate and after proper training, you or your caregiver have the ability to give it in the comfort of your own home.

ENSPRYNG is for adults with AQP4+ NMOSD who are:

• Newly diagnosed and exploring treatment options
• Currently receiving treatment for NMOSD with:
  • oral immunosuppressive therapies (ISTs) such as azathioprine, mycophenolate mofetil, or oral corticosteroids
  • approved or investigational monoclonal antibodies
• Uncertain about, or not responding well to, their current therapy

Do not take ENSPRYNG if you:

• are allergic to ENSPRYNG or any of the ingredients in ENSPRYNG
• have an active hepatitis B infection
• have active or untreated inactive (latent) tuberculosis

The specific way ENSPRYNG works is not completely understood, but it is thought to affect the protein interleukin 6 (IL-6). ENSPRYNG is the first treatment for NMOSD designed to block IL-6, a protein made by immune cells in our bodies that may play a key role in the inflammation that occurs in people with NMOSD.

ENSPRYNG has been studied both alone and with ISTs (eg, azathioprine, mycophenolate mofetil, or oral corticosteroids), but since every person is different, your doctor will need to decide what's best for you. Just remember to tell your doctor about every medicine you're taking before starting treatment.

Genentech Access Solutions will tell you which specialty pharmacy your health insurance plan wants you to use. When we check your coverage, we also refer you to a specialty pharmacy that can ship your Genentech medicine to your home or doctor's office.

Your specialty pharmacy might call you to confirm insurance and shipping details. Be sure you return all calls from the specialty pharmacy. This helps them send your Genentech medicine on time.

In 2 clinical studies, ENSPRYNG was proven to reduce the risk for relapse when used by itself or with certain immunosuppressive therapy. In both studies, more patients were relapse-free with ENSPRYNG than with placebo.

Want to know more about the ENSPRYNG studies? See its proven results here

ENSPRYNG may cause serious side effects including: infections, increased liver enzymes, and low neutrophil counts. All required vaccinations should be completed before starting ENSPRYNG. Do not take ENSPRYNG if you are allergic to satralizumab-mwge or any of the ingredients in ENSPRYNG, have an active hepatitis B infection, or have active or untreated inactive (latent) TB.

These are not all the possible serious side effects with ENSPRYNG. Talk to your healthcare provider if you experience side effects while taking ENSPRYNG.

The most common side effects of ENSPRYNG include:

• sore throat/runny nose (nasopharyngitis)
• rash
• fatigue
• extremity pain
• headache
• upper respiratory tract infection
• nausea
• inflammation of the stomach lining (gastritis)
• joint pain (arthralgia)

These are not all the possible side effects of ENSPRYNG. Talk to your healthcare provider if you experience side effects while taking ENSPRYNG.

ENSPRYNG is a subcutaneous injection that comes in a prefilled syringe. Once you've received 3 starting doses in the first 4 weeks of treatment and been trained and approved by your doctor to self-inject, you'll be able to take ENSPRYNG yourself or with the help of a caregiver, wherever you choose, every month.

Your doctor will train you to self-inject or teach your caregiver how to give you your medicine. If you or your caregiver would still like more training after that, you can set up a free, one-on-one session with a Clinical Education Manager* (CEM) either in person or virtually to receive supplemental injection training and educational materials to help you get more comfortable with the injections and learn more about ENSPRYNG and NMOSD.

*This program is intended primarily for patients prescribed ENSPRYNG who are in their first year of treatment. Clinical Education Managers are Genentech employees and do not give medical advice.

If you'd like to adjust your dosing schedule, please talk to your doctor before doing so. They can help you find a safe solution that better fits your needs.

If a starting dose is missed, you should take it immediately, then maintain the 2-week dosing interval from your new starting date until the first 3 doses are complete, and then continue with ongoing doses every 4 weeks.

If an ongoing dose is missed, you should take it immediately, wait the 4-week interval from your new starting date, and continue with ongoing doses every 4 weeks.

Speak with your doctor if you have any questions about how to restart treatment or if it has been more than 8 weeks since your last dose of ENSPRYNG.

ENSPRYNG should be stored in the refrigerator between 36°F to 46°F (2°C to 8°C) in the original carton. You can store ENSPRYNG at room temperature for up to 8 days, giving you control over where you take it.

If the seal is broken, your medication has expired, or there are any other issues with your medication, contact your doctor immediately. Do not use the medication.

If you have experienced this, we encourage everyone to report any side effects related to ENSPRYNG or other Genentech prescription drugs to Genentech, Inc. at 888-835-2555 and the FDA at 800-FDA-1088.

Yes, you can take ENSPRYNG with you wherever you'd like, as long as your doctor has trained and approved you to self-inject. Just be sure to stick to your regular dosing schedule and keep ENSPRYNG in a travel cooler whenever possible. You can store ENSPRYNG at room temperature (no higher than 86°F/30°C) for up to 8 days, giving you control over where you take it.

It's important to stay on track with your ENSPRYNG injections. Keep track of the date of each dose and where it was given (left abdomen, right abdomen, left thigh, or right thigh), as you'll need to rotate injection sites. Make note of any reactions and how you felt, so you can discuss with your doctor. It can help to set reminders of your upcoming injection days in your phone or calendar.

NMOSD stands for “neuromyelitis optica spectrum disorder” and is sometimes called “neuromyelitis optica” or “NMO” for short. It is a rare, chronic, autoimmune disease marked by inflammation of the optic nerves and spinal cord. NMOSD can cause relapses that result in new or worsening symptoms.

NMOSD symptoms can be different from person to person, so it's important to discuss any you experience with your doctor. Common symptoms include:

• blurred vision
• inability to see colors
• complete vision loss
• pain
• weakness
• paralysis in the legs
• loss of sensation or numbness
• bladder and bowel control issues
• severe hiccups
• vomiting
• nausea

AQP4+ is short for AQP4-IgG(+), which is short for aquaporin-4 immunoglobulin G. It's an antibody produced by the immune system that helps in diagnosing NMOSD. If you're curious about your AQP4-IgG antibody status, talk to your doctor about getting tested for it.

Up to 90% of people living with NMOSD experience relapses. If left untreated, relapses can lead to damage that is irreversible and progressive, meaning the more relapses you have, the worse your symptoms become over time, which is why it's so important to talk to your doctor about managing your NMOSD with a treatment like ENSPRYNG.

Anytime you experience a relapse, call your doctor immediately.

Your Patient Navigator from Genentech Access Solutions can help you understand your insurance coverage and assistance options. There may be options that may help you afford your medication, no matter what type of health insurance you have.

For more information, visit the Financial Assistance Options page or call 844-NSPRYNG (844-677-7964).

Yes. Along with the Injection Training Video and Administration Pocket Guide, 1:1 injection training is available with a Clinical Education Manager.* If you're interested, fill out this form to request support from a CEM.

*This program is intended primarily for patients prescribed ENSPRYNG who are in their first year of treatment. Clinical Education Managers are Genentech employees and do not give medical advice.

In addition to the ENSPRYNG website, there are several NMOSD advocacy organizations dedicated to providing valuable disease information and support to those who are living with or caring for someone with NMOSD. Check out the Helpful Resources page for more information.